Information material
06-12-2007
curasan AG: US-Registration for REVOIS® Dental Implant System
Kleinostheim, June, 12 2007 - curasan AG (ISIN DE 000 549 453 8) listed in the Prime Standard obtained the FDA-certification for her REVOIS® dental implant system. By this, the medical product is registered for distribution in the United States of America, and the product can be launched ahead of schedule within the ICOI World Congress in San Francisco by end of August 2007, by the company’s own sales organization, curasan Inc.
About curasan AG:
curasan AG (ISIN: DE 000 549 453 8), an exchange-listed company, is a leading innovator within the growth market of bone and tissue regeneration. The company has developed a comprehensive product range centred around its synthetic bone regeneration material Cerasorb®, for use in soft and hard tissue. With the REVOIS® implant system, the company’s sales is focusing more prominently on the growth market of dental surgery/implantology. The majority of new products emerging from the substantial development pipeline are to be offered under licence within other medical fields. Please visit curasan’s corporate website at www.curasan.com